Amgen (AMGN) director Amy E. Miles awarded 665 RSUs, now holds 5,640 shares

Rhea-AI Filing Summary

MILES AMY E reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. director Amy E. Miles received an equity award of 665 shares of common stock as a grant under the company’s director incentive program. The award, structured as Restricted Stock Units that vested immediately and settle one-for-one in common shares, increased her direct holdings to 5,640 shares. This total includes 408 dividend equivalents credited to her unvested RSUs under a qualifying dividend reinvestment plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MILES AMY E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	--

Holdings After Transaction: Common Stock — 5,640 shares (Direct, null)

Footnotes (1)

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU grant size: 665 shares Grant price: $0.00 per share Total shares after grant: 5,640 shares +1 more

4 metrics

RSU grant size 665 shares Restricted Stock Units granted to director on 2026-05-19

Grant price $0.00 per share Equity award under director incentive program

Total shares after grant 5,640 shares Direct Amgen common stock holdings following transaction

Dividend equivalents included 408 DEs DEs credited to unvested RSUs and included in total holdings

Key Terms

Restricted Stock Units (RSUs), Director Incentive Program, dividend reinvestment plan, Dividend Equivalents (DEs)

4 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Director Incentive Program financial

"granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended"

dividend reinvestment plan financial

"subject to a qualifying dividend reinvestment plan"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Dividend Equivalents (DEs) financial

"These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILES AMY E

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	5,640(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Amy E. Miles	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amgen (AMGN) director Amy E. Miles report on this Form 4?

Amy E. Miles reported receiving a grant of 665 Restricted Stock Units that vest immediately and are paid in Amgen common stock. This equity award was made under Amgen’s director incentive program and increases her overall direct share ownership in the company.

How many Amgen (AMGN) shares does Amy E. Miles hold after this transaction?

After the reported grant, Amy E. Miles directly holds 5,640 Amgen common shares. This figure includes 408 dividend equivalent units tied to her unvested RSUs, which will also pay out in common stock according to their vesting schedule and plan terms.

Was Amy E. Miles’ Amgen (AMGN) equity award an open-market purchase or a compensation grant?

The transaction is a compensation grant, not an open-market purchase. The 665 shares were awarded at a price of $0.00 per share as Restricted Stock Units under Amgen’s 2009 Director Incentive Program, rather than being bought on the stock market.

What are the key terms of the Amgen (AMGN) RSUs granted to Amy E. Miles?

The Restricted Stock Units vest immediately and are paid one-for-one in Amgen common stock. Directors may defer payment under a chosen schedule. Related dividend equivalent units are credited to unvested RSUs and paid in shares along with cash for any remaining fractional amounts.

What are dividend equivalents (DEs) in Amy E. Miles’ Amgen (AMGN) holdings?

Dividend equivalents are units credited to her unvested RSUs under a dividend reinvestment plan. For Amy E. Miles, 408 DEs are included in her reported 5,640 shares and will be paid in Amgen common stock as the underlying RSUs vest, plus cash for fractional shares.